These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 32250190)
1. Pupil Diameter, Corneal Thickness, and Anterior Chamber Alterations Following Topical Olopatadine Hydrochloride 0.1%: A Single-Masked Randomized Controlled Clinical Study. Çavdarli C; Topcu Yilmaz P J Ocul Pharmacol Ther; 2020 Sep; 36(7):540-544. PubMed ID: 32250190 [No Abstract] [Full Text] [Related]
2. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits. Iyer GR; Cason MM; Womble SW; Li G; Chastain JE J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192 [TBL] [Abstract][Full Text] [Related]
3. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Spangler DL; Abelson MB; Ober A; Gotnes PJ Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132 [TBL] [Abstract][Full Text] [Related]
4. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Dogru M; Ozmen A; Ertürk H; Sanli O; Karatas A Clin Ther; 2002 Aug; 24(8):1309-21. PubMed ID: 12240781 [TBL] [Abstract][Full Text] [Related]
5. Changes in the shape of the anterior and posterior corneal surfaces caused by mydriasis and miosis: detailed analysis. Saitoh K; Yoshida K; Hamatsu Y; Tazawa Y J Cataract Refract Surg; 2004 May; 30(5):1024-30. PubMed ID: 15130639 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525 [TBL] [Abstract][Full Text] [Related]
7. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F Expert Opin Pharmacother; 2017 Aug; 18(11):1137-1143. PubMed ID: 28656804 [TBL] [Abstract][Full Text] [Related]
8. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model. McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427 [TBL] [Abstract][Full Text] [Related]
9. Central corneal thickness, anterior chamber depth, and pupil diameter measurements using Visante OCT, Orbscan, and Pentacam. Yazici AT; Bozkurt E; Alagoz C; Alagoz N; Pekel G; Kaya V; Yilmaz OF J Refract Surg; 2010 Feb; 26(2):127-33. PubMed ID: 20163077 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Mah FS; O'Brien T; Kim T; Torkildsen G Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176 [TBL] [Abstract][Full Text] [Related]
11. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G; Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286 [TBL] [Abstract][Full Text] [Related]
12. Orbscan corneal topography system in evaluating the anterior structures of the human eye. Cosar CB; Sener AB Cornea; 2003 Mar; 22(2):118-21. PubMed ID: 12605044 [TBL] [Abstract][Full Text] [Related]
13. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Abelson MB; Spitalny L Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Spangler DL; Bensch G; Berdy GJ Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863 [TBL] [Abstract][Full Text] [Related]
15. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057 [TBL] [Abstract][Full Text] [Related]
16. Wearing Swimming Goggles Reduces Central Corneal Thickness and Anterior Chamber Angle, and Increases Intraocular Pressure. Jiménez R; Molina R; García JA; Redondo B; Vera J Curr Eye Res; 2020 May; 45(5):535-541. PubMed ID: 31526280 [No Abstract] [Full Text] [Related]
17. Differences of the anterior segment parameters in children with down syndrome. Aslan L; Aslankurt M; Aksoy A; Gümüşalan Y Ophthalmic Genet; 2014 Jun; 35(2):74-8. PubMed ID: 24797960 [TBL] [Abstract][Full Text] [Related]
18. The effect of mydriasis from phenylephrine on corneal shape. Huang RY; Lam AK Clin Exp Optom; 2007 Jan; 90(1):44-8. PubMed ID: 17177665 [TBL] [Abstract][Full Text] [Related]
19. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Greiner JV; Udell IJ Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305 [TBL] [Abstract][Full Text] [Related]
20. Influences of topical cyclopentolate on anterior chamber parameters with a dual-Scheimpflug analyzer in healthy children. Güler E; Güragaç FB; Tenlik A; Yagci R; Arslanyilmaz Z; Balci M J Pediatr Ophthalmol Strabismus; 2015; 52(1):26-30. PubMed ID: 25403030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]